Stemline Therapeutics: 2Q Earnings Snapshot
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Thursday reported a loss of $18.9 million in its second quarter.
The New York-based company said it had a loss of 66 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 63 cents per share.
The biopharmaceutical company posted revenue of $500,000 in the period.
Stemline Therapeutics shares have decreased 9 percent since the beginning of the year. The stock has climbed 66 percent in the last 12 months.